Mitiglinide insulin secretagogues

Description Results

mitiglinide 10 - 20 mg three times daily (n=291)

vs.

nateglinide 120 mg three times daily (n=0)

double-blind

Parallel groups

Sample size: 291/0

Primary endpoint:

FU duration: 20 weeks

additional mitiglinide 5 or 10 mg tid (n=-9)

vs.

placebo on top pioglitazone (n=-9)

multicenter

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 16 weeks

mitiglinide (n=-9)

vs.

on top of once daily insulin glargine (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: